Icahn Comments on MedImmune Sale Process

New York, April 16  /PRNewswire/ -- Several weeks ago, as a large shareholder of MedImmune, Inc. (NASDAQ:MEDI), Carl Icahn informed the company that, because of lackluster performance over the last four or five years, he believed the best course of action was to put the company up for sale and that he intended to nominate an opposing slate at the upcoming 2007 annual meeting, whose intention it would be to accomplish this.

Now that the MedImmune board has announced it intends to sell the company, Mr. Icahn stated that, at the present time, he no longer intends to put forth an opposition slate.  However, he also stated that he reserves the right to launch a proxy contest in the event that MedImmune does not successfully complete the sale transaction.  He indicated that he will be closely monitoring the Company's efforts in order to help assure that they will result in a transaction that will maximize value for all stockholders. 

DATASOURCE: Carl Icahn



CONTACT:  Susan Gordon, [phone], for Carl Icahn

Copyright